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This communication reports the first demonstration of the 
detection of Streptococcus pneumoniae and Neisseria 
meningitidis bacterial DNA extracted from anonymous 
patient CSF samples and assesses the applicability of a 
previously developed SERS based DNA detection assay as a 
platform for the detection of multiple meningitis pathogens 
from clinical samples. 
Introduction 
There is a growing need for DNA detection methods that are both 
highly selective and sensitive.1 The most commonly used method of 
detection involves fluorescence-based techniques such as the 
polymerase chain reaction (PCR).2, 3 An alternative method of choice 
is surface enhanced Raman spectroscopy (SERS), which is known to 
be a sensitive, molecularly specific technique with the ability to 
detect multiple analytes simultaneously due to the characteristic 
fingerprint spectra obtained.4-6 To date, numerous assays have been 
developed for the direct detection of DNA using SERS.7-12 SERS has 
been shown to successfully detect individual DNA bases; however 
this does not allow for sequence specific detection as the order of 
bases is unknown.13 To overcome this, dye labels have been 
incorporated into DNA sequences to aid sequence specific detection. 
Fluorescent dyes produce characteristic SERS spectra that can be 
indicative of the presence of target disease DNA. The combination 
of SERS and fluorescent dye labelled DNA has been used 
successfully to detect the cystic fibrosis trans-membrane 
conductance regulator (CFTCR) gene,14 sequences coding for 
methicillin-resistant Staphylococcus aureus (MRSA)12, 15 and 
furthermore Vo-Dinh et al. developed a SERS-based assay using 
³PROHFXODUVHQWLQHOV´IRUWKHPXOWLSOH[GHWHFWLRn of two biomarkers 
for breast cancer.16 
Meningitis is a result of inflammation of the lining around the spinal 
cord and brain. The majority of meningitis cases are viral in which 
case the treatment is directed at limiting the effects of the 
symptoms.17, 18 However, bacterial meningitis is more serious in 
comparison, where urgent medical attention and antibiotic 
administration is required. The three most common bacterial 
pathogens associated with meningitis and septicaemia are Neisseria 
meningitidis, Streptococcus pneumoniae and Haemophilus 
influenzae.19 These are commonly identified using culture-based 
methods that can be time consuming and at time unreliable. The 
main issue surrounding the diagnosis of the specific pathogen 
causing meningitis is that upon admission the patients are 
immediately administered antibiotics, which can obscure the results 
obtained from the culture based methods making positive pathogen 
identification difficult. For successful patient treatment, accurate 
pathogen identification is required to allow for the correct antibiotics 
to be administered. 
We have previously shown the success of a SERS-based assay for 
the multiplex detection and quantification of DNA from three 
pathogens Neisseria meningitidis, Streptococcus pneumoniae and 
Haemophilus influenzae (Figure 1).20 DNA relating to each pathogen 
was detected individually using the assay with picomolar detection 
limits. Additionally, PCR was performed on plasmid DNA of each 
pathogen as proof of concept of the ability of the assay to be used in 
a clinical setting. This was shown to be successful and, more 
importantly, with the use of chemometric analysis pathogen 
quantification was possible using SERS for the first time. Here we 
report the first study to identify pathogen DNA in patient samples to 
crucially establish if the assay is suitable for use in hospital 
laboratories.  
Results and Discussion 
Clinical samples from anonymous patients containing two 
pathogens, Streptococcus pneumoniae and Neisseria meningitidis 
were provided by the national reference laboratory, SHLMPRL. The 
mean age of the patients was 43 years with a median of 25 reflecting 
the very young and old age groups presenting with these disease 
groups. The samples provided are historical, having been previously 
analysed by Glasgow Royal Infirmary and have been stored over a 
long period of time, therefore it must be noted that DNA degradation 
is possible in some of the samples making pathogen identification 
using the SERS-based assay difficult. 
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Figure 1 Schematic of the SERS detection assay illustrating each step involved. After 
the pathogen DNA is extracted from the CSF, PCR is performed (a), which amplifies the 
amount of each pathogen present to enable further analysis. The amplified pathogen 
DNA is added to a solution of reporter (blue) and capture (purple) probes for 
hybridisation (b). As the capture probe possesses a biotin group, streptavidin coated 
magnetic beads are added to retain the newly formed duplex and remove and excess 
DNA (c). Lambda exonuclease is added, to digest and release the reporter probe that 
EHDUVD¶SKRVShate to initiate enzymatic DNA digestion, from the duplex allowing the 
fluorescent label to be free in solution (d). The products of the enzymatic digestion are 
added to a solution of spermine and silver nanoparticles (e). SERS analysis is then 
performed and the characteristic SERS spectra of the fluorescent labels are obtained (f). 
8VLQJ D 4LDJHQ 4,$DPS '1$ PLQL NLW EDFWHULDO DNA was 
extracted from cerebral spinal fluid (CSF) and blood from patients 
admitted to hospital showing a variety of symptoms including sepsis 
and meningitis. Previously used methods for detecting bacterial 
meningitis pathogens were culture-based techniques that would 
potentially take up to 36 hours for a positive diagnosis.21, 22 The time 
scale for obtaining a positive diagnosis from the clinical samples 
using the above SERS-based assay (Figure 1) would be in the region 
of 5 hours.  
Prior to the SERS-based assay being performed, PCR was performed 
on the DNA from clinical samples as previously described.23 
Positive DNA samples were then used in SERS. Synthetic primers, 
specific to the pathogens, were used along with the commercially 
available Qiagen PCR kit to obtain amplified pathogen DNA. Two 
PCR reactions were performed simultaneously; one contained the 
pathogen DNA to be amplified and one omitting this from the 
sample mixture (no-template control, NTC). Following this, the 
amplified DNA, or the NTC product, was added to the sample 
mixture containing two probes; capture and reporter probe. A 
sandwich hybridisation step was performed where both probes 
hybridise to the single strand of amplified pathogen DNA, if it is 
present. The capture probe possesses a biotin modification, which 
when in the presence of streptavidin coated magnetic beads allows 
for wash steps to be carried out and removal of any excess/non-
specific components from the reaction mixture and retaining only the 
newly formed duplex. Enzymatic digestion then takes place using 
the enzyme lambda exonuclease, which digests the fluorescently 
labelled reporter probe from the duplex, releasing the fluorescent 
dye label into solution. Again, using the strong interaction between 
biotin and streptavidin, the supernatant containing the fluorescent 
dye label is removed and added to a mixture of silver nanoparticles 
and spermine allowing for subsequent SERS analysis. Obtaining the 
SERS spectrum of the fluorescent dye label is indicative of the 
presence of the bacterial meningitis pathogen and therefore 
providing a positive diagnosis.  
In total, 28 samples were analysed, 19 of these samples gave poor 
results from PCR amplification due to sample degradation however 
9 samples produced results to allow for pathogen identification. The 
pathogen Neisseria meningitidis was detected when the spectrum of 
the fluorescent dye fluorescein (FAM) was observed. FAM was the 
fluorescent label attached to the reporter probe, which was 
complementary to the Neisseria meningitidis DNA sequence. PCR 
was performed on the clinical samples provided. Results from three 
of these samples are shown in Figure 2. When Neisseria meningitidis 
pathogen DNA is present, the characteristic FAM SERS spectrum is 
observed (red spectra) in each case showing peaks at 635, 1325 and 
1635 cm-1. As mentioned above, a control experiment (NTC) was 
also carried out to confirm SERS intensity is only observed when the 
pathogen is present (black spectra). A low intensity SERS spectrum 
is observed, particularly in Figure 2b. This could occur when the 
reporter probe has not been efficiently removed from the streptavidin 
beads and some has remained and will produce signal in the final 
SERS analysis step. Increasing the number of wash steps prior to 
enzymatic digestion could reduce this. However, the discrimination 
between the positive sample and the NTC was large and therefore 
positive identification is possible. 
 
Figure 2 SERS spectra of FAM labelled probe obtained when Neisseria meningitidis 
pathogen PCR product from DNA extracted from patient samples was present (red) and 
the no-template control, NTC (black). The three spectra, a-c, are of three different 
clinical samples analysed using the SERS-based assay. SERS spectra were recorded 
using an excitation wavelength of 532 nm with an accumulation of 1 second. 
DNA extracted from patient samples containing the second 
pathogen, Streptococcus pneumoniae, was detected in the same way. 
To determine the presence of this pathogen, the reporter probe 
complementary to the Streptococcus pneumoniae DNA sequence 
was labelled with tetramethylrhodamine (TAMRA) and when the 
SERS spectrum of TAMRA was observed positive pathogen 
identification was possible. PCR was again performed prior to the 
SERS assay, to amplify the amount of Streptococcus pneumoniae 
pathogen DNA to facilitate SERS detection. Two PCR experiments 
were performed; one where pathogen DNA was present and another 
where it was absent (NTC). When the characteristic TAMRA peaks 
at 1375 and 1650 cm-1 were observed, this was confirmation that the 
bacterial pathogen, Streptococcus pneumoniae, was present in the 
clinical sample (red spectra), Figure 3. As observed with the results 
from Neisseria meningitidis (Figure 2), peak intensities were 
observed in the NTC (black spectra), which is a result of the 
presence of the reporter probe post-washing before SERS analysis. 
This can be rectified by increasing the number of wash steps in the 
SERS-based assay. The intensity observed in the TAMRA NTC 
spectra are higher than those compared to the FAM NTC spectra due 
to the fact TAMRA has a larger Raman cross section compared to 
FAM, therefore will produce a higher SERS intensity spectra when 
present.  
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Figure 3 SERS spectra of TAMRA labelled probe obtained when using Streptococcus 
pneumoniae pathogen PCR product (red) and the no-template control, NTC (black). The 
three spectra, a-c, are of three different clinical samples analysed using the SERS-based 
assay. SERS spectra were recorded using an excitation wavelength of 532 nm with an 
accumulation of 1 second.  
When a patient is admitted presenting symptoms of bacterial 
meningitis, to provide the most efficient course of treatment it is 
imperative to provide positive identification of multiple pathogens in 
a short time scale. The SERS assay has previously been shown to 
successfully detect three bacterial meningitis pathogens 
simultaneously, which did not involve clinical samples. The two 
pathogens; Neisseria meningitidis and Streptococcus pneumoniae 
present in the clinical samples, were to be detected simultaneously 
for the first time using the SERS-based assay. The samples provided 
by the Glasgow Royal Infirmary only contain one pathogen per 
sample. However, it is important to have the ability to screen for 
multiple pathogens using multiple probes and fluorescent labels. 
Therefore, PCR was performed using two approaches: one where the 
two pathogens were amplified simultaneously in the same reaction 
mixture and another where amplification of each pathogen occurred 
in separate reaction tubes and were mixed prior to the assay being 
performed, results are shown in Figure 4 a and b respectively. The 
spectra obtained when the two pathogens were present (green 
spectra) contain characteristic peaks of both FAM and TAMRA, 
which are highlighted. Regardless of the chosen method of PCR 
amplification, both pathogens can be detected simultaneously. 
However, the simultaneous amplification approach is preferred as it 
decreases the time taken to obtain a positive result and reduces the 
amount of samples that are analysed. This is an encouraging result as 
it demonstrates the assay can be used successfully to detect multiple 
pathogens in a single patient sample. 
 
Figure 4 SERS spectra obtained when detecting both Neisseria meningitidis (FAM) and 
Streptococcus pneumoniae (TAMRA) simultaneously (green spectra). For reference, the 
characteristic spectra of TAMRA (blue) and FAM (red) are shown. Two PCR methods 
were used, one where the two pathogens were amplified in the same tube (a) and in 
separate tubes (b) then mixed prior to the assay being performed. Characteristic peaks of 
both dyes are highlighted. SERS spectra were recorded using an excitation wavelength 
of 532 nm with an accumulation of 1 second. 
Conclusions 
This study shows the ability of a SERS-based assay to detect two 
bacterial meningitis pathogens present in clinical samples of patients 
with confirmed bacterial meningitis. This was done both individually 
and simultaneously with equally successful results. This is the first 
report of bacterial meningitis pathogen DNA extracted from patient 
clinical samples then amplified by PCR has been detected using 
SERS. From the 28 clinical samples provided, 9 gave excellent 
discrimination to allow for pathogen identification using the SERS 
assay. The assay used is not limited to the detection of bacterial 
meningitis pathogens since changing the sequences of the capture 
and reporter probes, a variety of infectious diseases can be detected 
on a clinical platform.  
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